• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Can individualized sunitinib dose and schedule changes optimize outcomes for kidney cancer patients?个体化的舒尼替尼剂量和给药方案调整能否优化肾癌患者的治疗结局？
Can Urol Assoc J. 2016 Nov-Dec;10(11-12Suppl7):S252-S255. doi: 10.5489/cuaj.4293.
2
Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.接受个体化舒尼替尼治疗的转移性肾细胞癌患者的疗效：与动态微泡超声数据的相关性及文献综述
Urol Oncol. 2014 May;32(4):480-7. doi: 10.1016/j.urolonc.2013.10.004. Epub 2013 Dec 8.
3
Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature.
Urol Oncol. 2015 Apr;33(4):171-8. doi: 10.1016/j.urolonc.2015.03.003.
4
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.舒尼替尼在转移性肾细胞癌患者中 2/1 方案给药：RAINBOW 分析。
Ann Oncol. 2015 Oct;26(10):2107-13. doi: 10.1093/annonc/mdv315. Epub 2015 Jul 27.
5
A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysis.一种用于转移性肾细胞癌的新型舒尼替尼改良方案：一项回顾性分析。
Acta Biomed. 2012 Aug;83(2):88-94.
6
[Alternative prescription schedules of sunitinib in metastatic kidney cancer: from the underground to the light?].[舒尼替尼在转移性肾癌中的替代给药方案：从地下走向光明？]
Bull Cancer. 2014 Sep;101(9):832-40. doi: 10.1684/bdc.2014.2020.
7
Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction.电离辐射与舒尼替尼的优化治疗方案可提高抗肿瘤活性并实现剂量降低。
Cancer Med. 2015 Jul;4(7):1003-15. doi: 10.1002/cam4.441. Epub 2015 Mar 31.
8
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.舒尼替尼作为一线治疗转移性肾细胞癌的个体化方案的疗效和安全性：一项 2 期临床试验。
Eur J Cancer. 2019 Feb;108:69-77. doi: 10.1016/j.ejca.2018.12.006. Epub 2019 Jan 14.
9
Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.舒尼替尼两周给药、一周停药方案治疗转移性肾细胞癌的 II 期研究。
J Clin Oncol. 2018 Jun 1;36(16):1588-1593. doi: 10.1200/JCO.2017.77.1485. Epub 2018 Apr 11.
10
Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.替西罗莫司替代舒尼替尼用于转移性肾细胞癌治疗的可行性、安全性和有效性：一项回顾性研究。
Drugs R D. 2017 Dec;17(4):585-596. doi: 10.1007/s40268-017-0209-5.

引用本文的文献

1
Evaluation of and Current Trends in the Management of Gastrointestinal Stromal Tumors: A Systematic Review.胃肠道间质瘤管理的评估及当前趋势：一项系统综述
Cureus. 2022 Jul 14;14(7):e26848. doi: 10.7759/cureus.26848. eCollection 2022 Jul.
2
Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021.晚期肾癌的管理：加拿大肾癌研究网络（KCRNC）2021年共识更新
Can Urol Assoc J. 2021 Apr;15(4):84-97. doi: 10.5489/cuaj.7245.
3
Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.晚期肾癌的管理：加拿大肾癌研究网络（KCRNC）2019年共识更新
Can Urol Assoc J. 2019 Oct;13(10):343-354. doi: 10.5489/cuaj.6256.
4
Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.晚期肾癌的管理：2017年加拿大肾癌论坛（CKCF）共识更新
Can Urol Assoc J. 2017 Oct;11(10):310-320. doi: 10.5489/cuaj.4769.

本文引用的文献

1
RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.舒尼替尼四周给药、两周停药与两周一疗程、一周停药治疗转移性透明细胞型肾细胞癌的随机 II 期临床试验：RESTORE 试验。
Ann Oncol. 2015 Nov;26(11):2300-5. doi: 10.1093/annonc/mdv357. Epub 2015 Sep 7.
2
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.舒尼替尼在转移性肾细胞癌患者中 2/1 方案给药：RAINBOW 分析。
Ann Oncol. 2015 Oct;26(10):2107-13. doi: 10.1093/annonc/mdv315. Epub 2015 Jul 27.
3
Sunitinib dosing schedule 2/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma.舒尼替尼2/1给药方案可提高中国转移性肾细胞癌患者的耐受性、疗效及健康相关生活质量。
Urol Oncol. 2015 Jun;33(6):268.e9-15. doi: 10.1016/j.urolonc.2015.03.008. Epub 2015 Apr 8.
4
Alternate sunitinib schedules in patients with metastatic renal cell carcinoma.转移性肾细胞癌患者使用舒尼替尼的交替给药方案。
Ann Oncol. 2015 Jul;26(7):1300-4. doi: 10.1093/annonc/mdv030. Epub 2015 Jan 26.
5
Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.舒尼替尼剂量递增克服了透明细胞肾细胞癌中的短暂性耐药，并与表观遗传修饰相关。
Mol Cancer Ther. 2015 Feb;14(2):513-22. doi: 10.1158/1535-7163.MCT-14-0208. Epub 2014 Dec 17.
6
Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.帕唑帕尼暴露量与晚期肾细胞癌患者临床安全性及疗效之间的关系。
Br J Cancer. 2014 Nov 11;111(10):1909-16. doi: 10.1038/bjc.2014.503. Epub 2014 Oct 28.
7
Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study.用于个体化帕唑帕尼给药的治疗药物监测：一项药代动力学可行性研究。
Ther Drug Monit. 2015 Jun;37(3):331-8. doi: 10.1097/FTD.0000000000000141.
8
Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.口服抗癌药物：有限的给药选择和剂量减少如何影响对照试验中的结果和患者的疗效。
J Clin Oncol. 2014 May 20;32(15):1620-9. doi: 10.1200/JCO.2013.53.0204. Epub 2014 Apr 7.
9
Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients.抗血管内皮生长因子治疗 mRCC：亚裔和非亚裔患者的差异。
Br J Cancer. 2014 Mar 18;110(6):1433-7. doi: 10.1038/bjc.2014.28. Epub 2014 Feb 18.
10
Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.舒尼替尼给药方案调整为 2 周用药、1 周停药在转移性肾细胞癌患者中的耐受性更好--与标准 4 周用药、2 周停药方案比较。
Jpn J Clin Oncol. 2014 Mar;44(3):270-7. doi: 10.1093/jjco/hyt232. Epub 2014 Jan 27.

个体化的舒尼替尼剂量和给药方案调整能否优化肾癌患者的治疗结局？

Can individualized sunitinib dose and schedule changes optimize outcomes for kidney cancer patients?

作者信息

Bjarnason Georg A

机构信息

Division of Medical Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada.

出版信息

Can Urol Assoc J. 2016 Nov-Dec;10(11-12Suppl7):S252-S255. doi: 10.5489/cuaj.4293.

DOI:10.5489/cuaj.4293
PMID:28096939
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5215304/
Abstract

The recommended starting dose and schedule for sunitinib is 50 mg daily for 28 days, followed by a 14-day break with significant dose reductions to 37.5 mg (75% of starting dose), and then 25 mg (50% of starting dose) on the same schedule (four/two schedule). There are several reasons why these dose and scheduling recommendations may not be optimal for most patients, as outlined below.

摘要

舒尼替尼的推荐起始剂量和给药方案为每日50毫克，服用28天，随后停药14天，并大幅减量至37.5毫克（起始剂量的75%），然后按照相同方案（4/2方案）服用25毫克（起始剂量的50%）。如下所述，这些剂量和给药方案建议对大多数患者而言可能并非最佳，原因有几点。